Search results
Showing 76 to 90 of 109 results for ovarian cancer
One-piece closed bags for colostomies: late-stage assessment (HTG754)
Late stage assessment (LSA) guidance on one-piece closed bags for colostomies
View recommendations for HTG754Show all sections
This guidance has been replaced by NICE technology appraisal guidance 55.
This guidance has been replaced by NICE technology appraisal guidance 91.
Molecular testing strategies for Lynch syndrome in people with colorectal cancer (HTG430)
Evidence-based recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with colorectal cancer.
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
Urinary incontinence and pelvic organ prolapse in women: management (NG123)
This guideline covers assessing and managing urinary incontinence and pelvic organ prolapse in women aged 18 and over. It also covers complications associated with mesh surgery for these conditions.
Trabectedin for the treatment of relapsed ovarian cancer (TA222)
This guidance has been updated and replaced by NICE technology appraisal guidance 389.
Maximal cytoreductive surgery for advanced ovarian cancer (IPG757)
We have moved interventional procedures guidance 757 to become HealthTech guidance 668 This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Ultra-radical (extensive) surgery for advanced ovarian cancer (IPG470)
This guidance has been updated and replaced by NICE HealthTech guidance 688.
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer [TSID10701]
In development Reference number: GID-TA11157 Expected publication date: TBC
This guidance has been updated and replaced by NICE technology appraisal guidance 91.
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
Discontinued Reference number: GID-TA10377
Tests in secondary care to identify people at high risk of ovarian cancer (DG31)
We have moved Diagnostics guidance 31 to become HealthTech guidance 453. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
New age-based blood test thresholds recommended by NICE will help GPs catch ovarian cancer earlier
More women with ovarian cancer could be diagnosed earlier under proposed new NICE guidance that replaces a one-size-fits-all blood test threshold with personalised, age-based criteria.
Discontinued Reference number: GID-TA11033